Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.

被引：3
|
作者：
Cardoso, Fatima
Villanueva, Cristian
Royce, Melanie
Cruz, Felipe
Debled, Marc
Hegg, Roberto
Toyama, Tatsuya
Falkson, Carla Isadora
Jeong, Joon
Srimuninnimit, Vichien
Ozguroglu, Mustafa
Gradishar, William John
Azevedo, Sergio J.
Arce, Christina H.
Ridolfi, Antonia
Lin, Chinjune
Bachelot, Thomas Denis
机构：
[1] Champalimaud Fdn, Breast Unit, Champalimaud Clin Ctr, Lisbon, Portugal
[2] CHRU Besancon, Besancon, France
[3] Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA
[4] Inst Brasileiro Controle Canc, Mooca, Brazil
[5] Inst Bergonie, Bordeaux, France
[6] Hosp Perola Byington FMUSP, Ctr Referencia Saude Mulher, Sao Paulo, Brazil
[7] Nagoya City Univ, Grad Sch Med Sci, Dept Breast Surg, Nagoya, Aichi, Japan
[8] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[9] Yonsei Univ Hlth Syst, Seoul, South Korea
[10] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand
[11] Istanbul Univ, Istanbul, Turkey
[12] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[13] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
[14] Novartis Pharmaceut, E Hanover, NJ USA
[15] Novartis Pharmaceut SAS, Rueil Malmaison, France
[16] Ctr Leon Berard, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1010
引用
收藏
页数：5
相关论文
共 50 条
  • [1] BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)
    Royce, M.
    Villanueva, C.
    Ozguroglu, M.
    Bachelot, T.
    Azevedo, S.
    Melo Cruz, F.
    Hegg, R.
    Debled, M.
    Gradishar, W. J.
    Manlius, C.
    Ridolfi, A.
    Lin, J.
    Ringeisen, F.
    Cardoso, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [2] Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4
    Bachelot, T.
    Royce, M.
    Villanueva, C.
    Melo Cruz, F.
    Hegg, R.
    Falkson, C.
    Jeong, J.
    Srimuninnimit, V.
    Arce, C. H.
    Ridolfi, A.
    Lin, C.
    Gradishar, W.
    Ozguroglu, M.
    Cardoso, F.
    Azevedo, S.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [3] Everolimus (EVE) plus exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study
    Jerusalem, Guy Heinrich Maria
    Kovalenko, Elena
    Yardley, Denise A.
    De Boer, Richard H.
    Hurvitz, Sara A.
    Ejlertsen, Bent
    Blau, Sibel
    Ozguroglu, Mustafa
    Landherr, Laszlo
    Ewertz, Marianne
    Taran, Tanya
    Fan, Jenna
    Noel-Baron, Florence
    Louveau, Anne-Laure
    Burris, Howard A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial
    Royce, Melanie
    Bachelot, Thomas
    Villanueva, Cristian
    Ozguroglu, Mustafa
    Azevedo, Sergio J.
    Cruz, Felipe Melo
    Debled, Marc
    Hegg, Roberto
    Toyama, Tatsuya
    Falkson, Carla
    Jeong, Joon
    Srimuninnimit, Vichien
    Gradishar, William J.
    Arce, Christina
    Ridolfi, Antonia
    Lin, Chinjune
    Cardoso, Fatima
    [J]. JAMA ONCOLOGY, 2018, 4 (07) : 977 - 984
  • [5] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Noguchi, S.
    Rugo, H.
    Gnant, M.
    Feng, W.
    Taran, T.
    Baselga, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
  • [6] The Prognostic Impact of Adjuvant Endocrine Therapy by Age for Patients with Small Estrogen Receptor-Positive (ER plus ), Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer
    Takahashi, Yuko
    Sasada, Shinsuke
    Kondo, Naoto
    Hashimoto, Hiroya
    Terata, Kaori
    Kida, Kumiko
    Sagara, Yasuaki
    Naito, Yoichi
    Anan, Keisei
    Ueno, Takayuki
    Suto, Akihiko
    Kanbayashi, Chizuko
    Takahashi, Mina
    Nakamura, Rikiya
    Ishiba, Toshiyuki
    Tsuneizumi, Michiko
    Nishimura, Seiichiro
    Ozaki, Yukinori
    Shimomura, Akihiko
    Sakai, Takehiko
    Iwatani, Tsuguo
    Shigematsu, Hideo
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [7] Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.
    Constantinidou, Anastasia
    Marcou, Yiola
    Simmons, Timothy
    Bernhisel, Ryan
    Hughes, Elisha
    Meek, Stephanie
    Kakouri, Eleni I.
    Georgiou, Georgios
    Zouvani, Ioanna
    Savvidou, Gabriella
    Kuhl, Vanessa
    Doedt, Jennifer
    Wagner, Susanne
    Gutin, Alexander
    Lanchbury, Jerry
    Kronenwett, Ralf
    Rakha, Emad A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
    Chainitikun, Sudpreeda
    Long, James P.
    Rodriguez-Bautista, Ruben
    Iwase, Toshiaki
    Tripathy, Debu
    Fujii, Takeo
    Ueno, Naoto T.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 729 - 739
  • [9] PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib plus letrozole (P plus L)
    Dieras, V.
    Harbeck, N.
    Joy, A. A.
    Gelmon, K. A.
    Ettl, J.
    Verma, S.
    Lu, D.
    Gauthier, E. R.
    Schnell, P.
    Mori, A.
    Rugo, H. S.
    Finn, R. S.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [10] Neoadjuvant nivolumab (NIVO) plus palbociclib (PALBO) plus anastrozole (ANA) for estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8
    Jerusalem, G.
    Prat, A.
    Salgado, R. F.
    Reinisch, M.
    Saura, C.
    Ruiz Borrego, M.
    Nikolinakos, P.
    Filian, J.
    Ades, F.
    Huang, N.
    Mazzei-Abba, A.
    Tolaney, S. M.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S165 - S166
12345